Assembly Bio files 8-K/A to correct filing tag on Q2 2026 results release

Assembly Biosciences filed a Form 8-K/A on August 14, 2026, to amend its original August 13 Current Report. The company said this amendment corrects the submission header used to file the original Form 8-K, which had inadvertently tagged Item 2.02 as Item 2.01¹, and stated plainly that no changes have been made to the content of the Form 8-K.¹

The underlying release, reissued as Exhibit 99.1, still reports Assembly Bio's second quarter 2026 results and pipeline updates as originally disclosed. The company said it announced expansion of ABI-6250 into cholestatic liver diseases, including PBC and PSC, with a Phase 2 study anticipated to initiate in the first quarter of 2027¹, and that it completed a $115 million gross financing expected to extend funding beyond planned ABI-6250 Phase 2 studies in HDV and cholestatic liver diseases¹.

On the Gilead-partnered herpes program, Assembly Bio said it received the clinical development plan from Gilead Sciences for the HSV helicase-primase inhibitor program, which indicates GS-1179, formerly ABI-1179, has been selected to advance toward a Phase 2 trial in patients with recurrent genital herpes expected to start by the end of 2026¹. The company said its decision on whether to opt into the 40% U.S. cost-profit share will follow receipt and review of Gilead's commercial cost estimates, which will complete the opt-in package¹.

On finances, cash, cash equivalents and marketable securities totaled $320.4 million as of June 30, 2026, compared to $226.6 million as of March 31, 2026¹. The company said this position, including the first $75 million extension fee due from Gilead in the fourth quarter of 2026 following the third anniversary of the collaboration agreement, is projected to fund operations into 2029¹.